The paclitaxel-eluting stent in percutaneous coronary intervention: Part II - Comparison with the sirolimus-eluting stent, economics, and unanswered questions

Cardiology in Review

Volumn 14, Issue 3, 2006, Pages 143-150

  Ray, Gretchen M ^a   Nawarskas, James J ^a   Frishman, William H ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Drug eluting stent; Paclitaxel; Sirolimus; Stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; TICLOPIDINE;

ANGIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; CATHETERIZATION; CELL CYCLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG BINDING; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; ECONOMICS; FOLLOW UP; GRAFT REJECTION; HEALTH CARE COST; HEART INFARCTION; HEART REINFARCTION; HUMAN; META ANALYSIS; MITOSIS; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; REVASCULARIZATION; REVIEW; RISK REDUCTION; STENOSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED STATES;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY STENOSIS; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS;

EID: 33748471562     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000214683.72810.87     Document Type: Review

References (57)

1. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart. 2003;89:218-224.
2. Gruchalla KJA, Nawarskas JJ. The paclitaxel-eluting stent in percutaneous coronary intervention. Part I: background and clinical comparison to bare metal stents. Cardiol Rev. 2006;14:88-98.
3. Marx SO, Jayaraman T, Go L, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
4. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277-2283.
5. Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm. 2000;57:437-451.
6. Perin EC. Choosing a drug-eluting stent: a comparison between Cypher and Taxus. Rev Cardiovasc Med. 2005;6(suppl 1):S13-S21.
7. Blagosklonny MV, Darzynkiewicz Z, Halicka HD, et al. Paclitaxel induces primary and post mitotic G1 arrest in human arterial smooth muscle cells. Cell Cycle. 2004;3:1050-1056.
8. Levin AD, Vukmirovic N, Hwang CW, et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A. 2004;101:9463-9467.
9. Dobesh PP, Stacy ZA, Ansara AJ, et al. Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease. Pharmacotherapy. 2004;24:1554-1577.
10. Moliterno DJ. Healing Achilles - sirolimus versus paclitaxel. N Engl J Med. 2005;353:724-727.
11. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
12. Klugherz BD, Llanos G, Lieuallen W, et al. Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 2002;13:183-188.
13. Halkin A, Stone GW. Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the Taxus trials. J Interv Cardiol. 2004;17:271-282.
14. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
15. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis. JAMA. 2005;293:165-171.
16. Goy JJ, Stauffer JC, Siegenthaler M, et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology, the TAXI trial. J Am Coll Cardol. 2005;45:308-311.
17. Ong ATL, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-stent evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol. 2005;45:1135-1141.
18. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the 'real world': the rapamycin-eluting stent evaluated at Rótterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109:190-195.
19. Valgimigli M, Malagutti P, Aoki J, et al. Sirolimus-eluting versus paclitaxel-eluting stent implantation for the percutaneous treatment of left main coronary artery disease. A combined RESEARCH and T-SEARCH long-term analysis. J Am Coll Cardiol. 2006;47:507-514.
20. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimuseluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663-670.
21. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353:653-662.
22. Lee SH, Ko YG, Jang Y, et al. Sirolimus- versus paclitaxel-eluting stent implantation for unprotected left main coronary artery stenosis. Cardiology. 2005;104:181-185.
23. Mehilli J, Dibra A, Kastrati A, et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J. 2006;27:260-266.
24. Morice MC, Colombo A, Beier B, et al for the REALITY Trial Investigators. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions. The REALITY Trial: a randomized controlled trial. JAMA. 2006;295:895-904.
25. Brener SJ. Wish list and REALITY: choice of stents and end points for treatment of de novo coronary artery lesions [editorial]. JAMA. 2006;295:937-938.
26. de Lezo J, Medina A, Pan M, et al. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study [Abstract]. J Am Coll Cardiol. 2005;45(suppl A):75A.
27. de Lezo J, Medina A, Pan M, et al. Drug-eluting stents for the treatment of chronic total occlusion. A randomized comparison of rapamycinversus paclitaxel-eluting stents [Abstract 2299]. Circulation. 2005;112(suppl II):II-477.
28. Sirolimus- versus paclitaxel-eluting stents for CTOs. Available at: http:// www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb=true&_pageLabel= TCTMDContent&hdCon=1348053. Accessed February 1, 2006.
29. Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent for the reduction of late lumen loss. Circulation. 2006;113:273-279.
30. Simonton C. STENT. Non randomized comparison of late clinical outcomes with paclitaxel-eluting and sirolimus-eluting stents from a large multicenter registry. Trans-catheter Cardiovascular Therapeutics 2005; October 16-21, 2005; Washington, DC. Results available at: http://theheart. org/viewArticle.do? primaryKey=584359&from=/searchLayout.do. Accessed February 1, 2006.
31. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005;294:819-825.
32. Windecker S. CYPHER vs TAXUS: an independent patient-based meta-analysis including the currently completed randomized controlled trials. Transcatheter Cardio-vascular Therapeutics 2005; October 16-21, 2005; Washington, DC. Results available at: http://theheart.org/viewArticle.do? primaryKey=584359&from=/ searchLayout.do. Accessed February 1, 2006.
33. Moreno R, Fernandez C, Alfonso F, et al. Comparison between Cypher and Taxus stents. Results from a meta-analysis including 5 randomized trials [Abstract 3067]. Circulation. 2005;112(suppl II):II-651.
34. Pan M, de Lezo J, Medina A, et al. Drug eluting-stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents [Abstract 2048]. Circulation. 2005;112(suppl II):II-422.
35. Di Lorenzo E, Varricchio A, Lanzillo T, et al. Paclitaxel and sirolimus stent implantation in patients with acute myocardial infarction [Abstract 2303]. Circulation. 2005;112(suppl II):II-478.
36. Airoldi F, Briguori C, Iakovou I, et al. Sirolimus and paclitaxel eluting stent implantation for diffuse coronary in-stent restenosis [Abstract 3069]. Circulation. 2005;112(suppl II):II-652.
37. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomized Basel Stent Kosten Effektivitats Trial (BASKET). Lancet. 2005;366:921-929.
38. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial. Circulation. 2004;110:508-514.
39. Lacey MJ, Clark MA, Halpern MT, et al. Estimated cost-effectiveness of the Taxus paclitaxel-eluting coronary stent [Abstract]. Am J Cardiol. 2003;92(suppl 6A):26L.
40. Mittmann N, Brown A, Seung SJ, et al. Economic Evaluation of Drug Eluting Stents. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment, 2005; Technology report no 53.
41. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part I. Circulation. 2002;106:516-520.
42. Grube E, Silber S, Hauptmann KE, et al. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am J Cardiol. 2005;96:79-82.
43. Serruys PW, Kutryk MJB, Ong ATL. Coronary-artery stents. N Engl J Med. 2006;354:483-495.
44. Salam AM, Al Suwaidi J, Holmes DR Jr. Drug-eluting coronary stents. Curr Probl Cardiol. 2006;31:1-120.
45. Frishman WH, Chiu R, Landzberg BR, et al. Medical therapies for the prevention of restenosis after percutaneous coronary interventions. Curr Probl Cardiol. 1998;23:534-635.
46. Wood S. Indian paclitaxel-eluting stent gets CE Mark of approval but can't encroach on Taxus turf. Available at: http://theheart.org/viewArticle.do? primaryKey=622093&from=/searchLayout.do. Accessed February 1, 2006.
47. Heuser S. What's next for stents? The Boston Globe. December 5, 2005.
48. Lee MS, Kapoor N, Jamal F, et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol. 2006;47:864-870.
49. Wong GB, Lee SS, Gollapudi RR, et al. Drug-eluting stents for coronary artery bypass graft lesions: low recurrent rates at 6 months [abstract]. J Am Coll Cardiol. 2006;47(Suppl B):47B.
50. Price MJ, Cristea E, Sawhney N, et al. Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. J Am Coll Cardiol. 2006;47:871-877.
51. Lefevre T, Darremont O, Morice M-C. Left main Taxus pilot study: mid-term follow up. J Am Coll Cardiol. 2006;47(Suppl B):46B.
52. Mishra S, Wolfram RM, Xue Z, et al. Comparison of clinical outcomes of implantation of drug-eluting stents with bare metal stents in large coronary arteries. J Am Coll Cardiol. 2006;47(Suppl B):46B.
53. Baim DS, Mauri L, Cutlip DC. Drug-eluting stenting for unprotected left main coronary artery disease [editorial]. J Am Coll Cardiol. 2006;47:878-881.
54. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 2004. Available at: www.acc.org/clinical/guidelines/stemi/index.pdf.
55. Wessely R, Schömig A, Kastrati A. Sirolimus and paclitaxel on polymer-based drug-eluting stents (viewpoint). J Am Coll Cardiol. 2006;57:708-714.
56. Waksman R, Buch AN, Kuchulakanti PK, et al. Sirolimus versus paclitaxel eluting stent experience in an unselected population with coronary artery disease (C-Versus T-REWARD Registries). J Am Coll Cardiol. 2006;47(Suppl B):20B.
57. Daemen J, Ong ATL, Valgimigli M, et al. Two-year clinical follow up of the unrestricted use of the paclitaxel-eluting stent compared to the sirolimus-eluting stent as part of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol. 2006;47(Suppl B):22B.